Immunogenicity in Cancer Nanomedicine
International Journal of Pharmaceutical Excipients · 2026
DOI: 10.66617/001c.171807 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Excipients, 2026. Verfasst von Aliyu Hussaini und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Pharmaceutical excipients are traditionally selected to improve drug solubility, stability, drug duration by influencing release or circulation time, formulation loading capacity and delivery efficiency. In cancer nanomedicine, however, these formulation components can also influence immune recognition, complement activation, biodistribution, pharmacokinetics and treatment outcomes, particularly during repeated administration. This opinion article examines excipient-driven immune responses in cancer nanomedicine, with emphasis on anti-excipient antibodies, accelerated blood clearance, complement activation-related pseudoallergy and reduced repeat-dose performance
Zitieren
APA
Hussaini, A., Musa, A., Abdullahi, H., Aliyu, M. A., Abbas, A. A., Mikailu, H., Alkali, F. B., & Enuma, K. (2026). Immunogenicity in Cancer Nanomedicine. International Journal of Pharmaceutical Excipients. https://doi.org/10.66617/001c.171807
Vancouver
Hussaini A, Musa A, Abdullahi H, Aliyu MA, Abbas AA, Mikailu H, et al. Immunogenicity in Cancer Nanomedicine. International Journal of Pharmaceutical Excipients. 2026. doi:10.66617/001c.171807
BibTeX
@article{Hussaini2026,
author = {Hussaini, Aliyu and Musa, Abba and Abdullahi, Huzaifa and Aliyu, Muhammad Amiru and Abbas, Arif Aliyu and Mikailu, Harisu and Alkali, Fatima Bashir and Enuma, Kingsley},
title = {Immunogenicity in Cancer Nanomedicine},
journal = {International Journal of Pharmaceutical Excipients},
year = {2026},
doi = {10.66617/001c.171807}
}
EUVIMED